BridgeBio Pharma (BBIO) Current Assets (2018 - 2026)
BridgeBio Pharma (BBIO) posted Current Assets of $1.2 billion for Q1 2026, up 55.6% sequentially from $797.7 million in Q4 2025, and up 78.56% YoY from $695.2 million in Q1 2025.
BridgeBio Pharma (BBIO) Current Assets (2018 - 2026) Analysis & Trends
BridgeBio Pharma has reported Current Assets for 9 years, with the latest figure at $1.2 billion in Q1 2026.
- Quarterly Current Assets rose 78.56% year-over-year to $1.2 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.2 billion (up 78.56% YoY) and the FY2025 annual result came in at $797.7 million, up 10.69% from the prior year.
- Current Assets grew to $1.2 billion in Q1 2026 per BBIO's latest filing, from $797.7 million in the prior quarter.
- Over five years, Current Assets peaked at $1.2 billion in Q1 2026 and troughed at $432.9 million in Q2 2023.
- A 5-year average of $693.0 million and a median of $695.2 million in 2025 frame the typical range for Current Assets.
- The sharpest annual moves came in 2023 and 2025: Current Assets slumped 43.87% in 2023, then jumped 88.8% in 2025.
- Over 5 years, Current Assets stood at $548.9 million in 2022, then decreased by 12.98% to $477.6 million in 2023, then surged by 50.9% to $720.7 million in 2024, then gained by 10.69% to $797.7 million in 2025, then surged by 55.6% to $1.2 billion in 2026.
- According to Business Quant data, Current Assets over the past three periods registered $1.2 billion, $797.7 million, and $839.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | BridgeBio Pharma | 15.60 Bn | 14.89 Bn | 228.63 Mn | 1.09 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.09 Bn |
| Mar 31, 2026 | 1.24 Bn |
| Dec 31, 2025 | 797.75 Mn |
| Sep 30, 2025 | 839.38 Mn |
| Jun 30, 2025 | 912.28 Mn |
| Mar 31, 2025 | 695.17 Mn |
| Dec 31, 2024 | 720.69 Mn |
| Sep 30, 2024 | 444.58 Mn |
| Jun 30, 2024 | 616.24 Mn |
| Mar 31, 2024 | 783.42 Mn |
| Dec 31, 2023 | 477.59 Mn |
| Sep 30, 2023 | 587.67 Mn |
| Jun 30, 2023 | 432.88 Mn |
| Mar 31, 2023 | 552.70 Mn |
| Dec 31, 2022 | 548.85 Mn |
| Sep 30, 2022 | 642.22 Mn |
| Jun 30, 2022 | 771.28 Mn |
| Mar 31, 2022 | 716.23 Mn |
| Dec 31, 2021 | 888.86 Mn |
| Sep 30, 2021 | 639.71 Mn |